- Home
- Publications
- Publication Search
- Publication Details
Title
Novel targeted treatment options for advanced cholangiocarcinoma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 9, Pages 709-720
Publisher
Informa UK Limited
Online
2018-08-20
DOI
10.1080/13543784.2018.1512581
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
- (2018) Thomas T DeLeon et al. Future Oncology
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway
- (2018) Minerva Daya et al. OncoTargets and Therapy
- Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss
- (2017) Kento Misumi et al. HISTOPATHOLOGY
- PD-L1 expression in extrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. HISTOPATHOLOGY
- Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
- (2017) Marie Bréchon et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer
- (2017) Hwajeong Lee et al. Therapeutic Advances in Gastroenterology
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
- (2016) Salvatore Galdy et al. CANCER AND METASTASIS REVIEWS
- A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
- (2016) Sumera Rizvi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
- (2016) Juliana Andrici et al. MEDICINE
- Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
- (2016) Supriya K. Saha et al. ONCOLOGIST
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
- (2016) Young Kwang Chae et al. Oncotarget
- Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells
- (2016) Xiwei Ding et al. Oncotarget
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
- (2015) Jacob M Wilson et al. Cancer Cell International
- Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
- (2015) A. Moeini et al. CLINICAL CANCER RESEARCH
- Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
- (2015) Mitesh J. Borad et al. CURRENT OPINION IN GASTROENTEROLOGY
- 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
- (2015) Y.J. Bang et al. EUROPEAN JOURNAL OF CANCER
- Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing
- (2015) Juan Putra et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited
- (2015) Luke Boulter et al. JOURNAL OF CLINICAL INVESTIGATION
- BAP1 mutation-associated cholangiocarcinoma: An aggressive disease.
- (2015) Deepa Anand et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
- (2015) Jean-Florian Guion-Dusserre et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Biliary papillomatosis with malignant transformation: A case report and review of the literature
- (2015) CHICHANG GU et al. Oncology Letters
- Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
- (2015) Daniela Sia et al. Nature Communications
- Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
- (2015) Daniel H. Ahn et al. Scientific Reports
- Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies
- (2015) Eric I Marks World Journal of Gastrointestinal Oncology
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
- (2014) Rondell P. Graham et al. HUMAN PATHOLOGY
- Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
- (2014) Jimme K. Wiggers et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism
- (2014) Jaime Acquaviva et al. MOLECULAR CANCER RESEARCH
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
- (2014) Mitesh J. Borad et al. PLoS Genetics
- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
- (2013) D. P. S. Sohal et al. ANNALS OF ONCOLOGY
- Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway
- (2013) Benjamin Goeppert et al. HEPATOLOGY
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- A Novel Armed Oncolytic Measles Vaccine Virus for the Treatment of Cholangiocarcinoma
- (2013) Sebastian Lange et al. HUMAN GENE THERAPY
- Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma
- (2013) Florian Ewald et al. INTERNATIONAL JOURNAL OF CANCER
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
- (2013) D Sia et al. ONCOGENE
- Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
- (2012) Giorgio Trinchieri Annual Review of Immunology
- Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
- (2012) Nicole Grabinski et al. Molecular Cancer
- Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
- (2012) P Wang et al. ONCOGENE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Risk factors for cholangiocarcinoma
- (2011) Gia L. Tyson et al. HEPATOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
- (2010) Ymera Pignochino et al. BMC CANCER
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
- (2010) W.-m. Zhao et al. CLINICAL CANCER RESEARCH
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now